Souhaitez-vous accéder aux communiqués récents ?

The case alleges that NuScale failed to disclose that it entrusted its NPM commercialization to an entity that lacked significant prior experience.

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva/Gazyvaro has the...

Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia...

TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

LOS ANGELES, March 05, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises NuScale Power Corporation, (“NuScale” or the "Company") (NYSE: SMR) investors off a class action on behalf of investors...

MALMÖ, Sweden, March 05, 2026 (GLOBE NEWSWIRE) -- Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world’s first and largest oat drink company, has announced a multi-year...

San Diego, CA, March 04, 2026 (GLOBE NEWSWIRE) -- TAP Real Estate Technologies, Inc. (OTC: RWAX) today announced the completion of its corporate name change from HUMBL, Inc. to TAP Real Estate...

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a...

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial Vancouver, Canada, March 04, 2026 (GLOBE...

HMG’s March 5 Phoenix Summit gathers C‑level tech leaders to explore AI, disruption, and iconic leadership. Two days left to register—don’t miss it.